CSIMarket
 

Celcuity Inc   (CELC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare

Celcuity Inc 's

Competitiveness


 

CELC Sales vs. its Competitors Q4 2023







Revenue Growth Comparisons




Net Income Comparison




<<  CELC Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Celcuity Inc Contracts

Investigating the Efficacy of Gedatolisib in Combination with Nubeqa for Metastatic Castration Resistant Prostate Cancer

Celcuity Inc., a clinical-stage biotechnology company, has initiated a Phase 1b/2 clinical trial (CELC-G-201) to evaluate the effectiveness of gedatolisib in combination with Nubeqa for the treatment of metastatic castration resistant prostate cancer (mCRPC). Gedatolisib, Celcuity's leading therapeutic candidate, is a powerful dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTORC1/2. This article aims to outline the key facts regarding the initiation of this clinical trial.Clinical Trial Details:The Phase 1b/2 clinical trial, CELC-G-201, conducted by Celcuity, has commenced with the administration of gedatolisib to its first patient. This trial aims to investigate the potential of gedat...





Who are Celcuity Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com